Navigation Links
Sorrento Therapeutics Adopts Stockholder Rights Plan
Date:11/12/2013

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Sorrento Therapeutics,  Inc. (NASDAQ: SRNE) announced that its Board of Directors adopted a stockholder rights plan (the "Rights Plan" or "Plan") and declared a dividend distribution of one right ("Right") for each outstanding share of Sorrento common stock.

The Rights Plan is intended to protect Sorrento and its stockholders from efforts to obtain control of Sorrento that the Board of Directors determines are not in the best interests of Sorrento and its stockholders, and to enable all stockholders to realize the long-term value of their investment in Sorrento. The Rights Plan is not intended to interfere with any merger, tender or exchange offer or other business combination approved by the Board of Directors.

Pursuant to the Plan, Sorrento is issuing one Right for each current share of common stock outstanding at the close of business on November 18, 2013. Initially, these rights will not be exercisable and will trade with the shares of Sorrento's common stock. If the Rights become exercisable, each Right will entitle stockholders to buy one one-thousandth of a share of a new series of participating preferred stock at an exercise price of $150 per Right.

The Rights will be exercisable only if a person or group acquires 15% or more of Sorrento's common stock in a transaction not approved by Sorrento's Board of Directors. If a person or group acquires 15% or more of Sorrento's outstanding common stock, each Right will entitle its holder (other than such person or members of such group) to purchase, at the Right's exercise price (subject to adjustment as provided in the Plan), a number of shares of Sorrento's common stock having a then-current market value of twice the exercise price.

In addition, if after a person or group acquires 15% or more of Sorrento's outstanding common stock, Sorrento merges into another company, an acquiring entity merges into Sorrento or Sorrento sells or transfers more than 50% of its assets, cash flow or earning power, then each Right will entitle the holder thereof to purchase, for the exercise price, a number of shares of common stock of the person engaging in the transaction having a then-current market value of twice the exercise price. The acquiring person will not be entitled to exercise these Rights.

Sorrento's Board of Directors may redeem the Rights for $0.001 per Right at any time before an event that causes the Rights to become exercisable. The Rights will expire on November 7, 2016, unless the Rights have previously been redeemed by the Board of Directors.

Additional details about the Rights Plan will be contained in a Form 8-K to be filed by Sorrento with the U.S. Securities and Exchange Commission.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for inflammation, metabolic, and infectious diseases. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary Antibody Drug Conjugates as well as Antibody formulated Drug Conjugates combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
2. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
3. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
4. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
5. Sorrento Therapeutics Completes IgDraSol Merger
6. Sorrento Therapeutics to Present at Two Healthcare Conferences
7. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
10. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
11. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... BARRINGTON, Ill. , May 10, 2017 ... medicine today; unfortunately its costs have also spiraled to ... are being sent to radiology than ever before as ... and diagnosis.  For a patient with lower back pain ... prove no anatomical reason for pain, resulting in entirely ...
Breaking Medicine Technology:
(Date:5/19/2017)... City, Mo (PRWEB) , ... May 19, 2017 , ... ... Saturday, May 20, his name will already appear on two major research studies that ... has been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside ...
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... The ... consulting to families and entrepreneurs throughout the California Central Valley, is announcing a joint ... of raising community support for a local kid’s camp event. , The Boys and ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... class of Beckman Young Investigators: , Victor Acosta, Ph.D. - University of New ... Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata ...
(Date:5/19/2017)... ... ... As a groundbreaking surgeon on the frontline of prostate cancer treatment, ... of the disease, he says, can make a world of difference. ... the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and its suggestion to ...
(Date:5/19/2017)... ... , ... CloSYS products which are marketed as the gentle giants of the ... gum health, which is linked to one’s overall health. Since 1991 when the CloSYS ... ways in which CloSYS products immediately helped eliminate bad breath as well as help ...
Breaking Medicine News(10 mins):